Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability.The analyst points out that Pyxis’ lead drug, PYX-201, is an ADC that targets Extradomain-B Fibronectin (EDB+FN) in the tumor stroma and releases a toxic payload into the tumor microenvironment.The analyst has initiated with an Overweight rating with a price target of $13.Stephens notes that ...